Artiva Biotherapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 24, 2025
ARTV$3.96-2.7%Stored close · as of Nov 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
Checking your notes…
(in thousands)
| YEAR ENDED DECEMBER 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities: | ||
| Net loss | $(65,373) | $(28,720) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 2,431 | 2,266 |
| Stock-based compensation | 6,980 | 7,053 |
| Change in fair value of SAFEs (including related party amounts of $2,911 and $573, respectively) | 3,597 | 707 |
| Accretion of discounts and amortization of premiums on investments, net | (2,342) | (456) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable (including related party amounts of $569 and $(569), respectively) | 1,034 | (510) |
| Other receivables (including related party amounts of $607 and $(607), respectively) | 578 | (724) |
| Prepaid expenses and other current assets | (1,965) | 516 |
| Other long-term assets | 125 | 139 |
| Accounts payable (including related party amounts of $76 and $51, respectively) | 519 | (408) |
| Accrued expenses (including related party amounts of $(1,447) and $(971), respectively) | (659) | (912) |
| Operating lease right-of-use asset and lease liabilities, net | 43 | 145 |
| Deferred revenue | — | (26,526) |
| Net cash used in operating activities | (55,032) | (47,430) |
| Investing activities: | ||
| Purchases of property and equipment | (642) | (3,258) |
| Purchases of short-term investments | (176,171) | (49,517) |
| Maturities of short-term investments | 56,350 | 26,800 |
| Net cash used in investing activities | (120,463) | (25,975) |
| Financing activities: | ||
| Proceeds from issuance of common stock, net of commissions | 166,507 | — |
| Proceeds from issuance of simple agreements for future equity (including related party amounts of $0 and $19,742, respectively) | — | 24,393 |
| Proceeds from exercise of stock options | 51 | 10 |
| Payments on finance leases | (149) | — |
| Cash paid in connection with IPO offering costs | (4,183) | — |
| Repurchase of restricted stock | — | (12) |
| Net cash provided by financing activities | 162,226 | 24,391 |
| Net decrease in cash, cash equivalents and restricted cash | (13,269) | (49,014) |
| Cash, cash equivalents and restricted cash at beginning of period | 53,762 | 102,776 |
| Cash, cash equivalents and restricted cash at end of period | $40,493 | $53,762 |
| Reconciliation of cash, cash equivalents and restricted cash to the balance sheet: | ||
| Cash and cash equivalents | $40,235 | $53,504 |
| Restricted cash | 258 | 258 |
| Total cash, cash equivalents and restricted cash | $40,493 | $53,762 |
| Supplemental disclosures of cash flow information: | ||
| Cash paid during the period for: | ||
| Income taxes | $— | $83 |
| Supplemental disclosures of noncash activities: | ||
| Property and equipment purchases in accounts payable and accrued liabilities | $57 | $18 |
| Conversion of SAFE notes to common stock | $28,697 | $— |
| Conversion of preferred stock to common stock | $216,413 | $— |
| Non-cash additions to financing leases | $241 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.